Danny Sullivan

About

Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
111 POSTS

/

0 COMMENTS

Articles

All the way from regenerative research to commercialisation

We speak to the director of the Wake Forest Institute of Regenerative Medicine – a research organisation with a clear focus on commercialisation. Just on...

Tonus seeks early-stage funding for exoskeleton tech

Company spawned by London start-up generator targets middle-aged recreational athletes with exoskeleton leggings powered by soft robotics. Back in November, we brought you the story...

SENISCA seeks funding for senescence reversal

University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology. Deep in the labs at the...

SyndicateRoom co-founder joins First Longevity

Tom Britton joins Advisory Panel as plans for Longevity equity funding platform take another step forward. Longevity.Technology: Just last month we announced the formation of...

Longevity investment: Apollo aims for the moon

Co-founder of Longevity-focused investment firm shows you can target aging AND appeal to biotech investors. Founded in 2016, Berlin and Boston-based Apollo already boasts an...

Leading academic “profoundly disappointed” by COVID-19 response

Professor Richard Faragher asks why developments in aging research have been largely ignored in the global response to the COVID-19 pandemic. With the world currently...

Exclusive interview: Professor Richard Faragher and cellular senescence

With senolytics driving investor interest in the Longevity sector, we speak to Professor Richard Faragher about resveratrol and the potential for rejuvenation of senescent...

VC enters Longevity market with K4Connect deal

We talk with VC investor Forte Ventures about its first foray into AgeTech, COVID-19 and the Longevity investment opportunity. Longevity agetech company K4Connect has announced...

New 3D bio-ink start-up targets neural tissue

Axolotl Biosciences introduces ThinkInk for stable, reproducible stem cell-derived neural tissues. Back in February, we spoke to the founder of Canadian 3D bioprinting start-up Aspect...